Immune Boost Capital is the venture subsidiary of the Arthritis National Research Foundation. We invest catalytic philanthropic capital into the earliest stages of autoimmune innovation — so breakthrough science can reach the patients waiting for it.
We evaluate every opportunity through a rigorous scientific lens, grounded in two decades of venture and operator experience across biopharma.
Every dollar invested is measured by a single standard: whether it meaningfully improves the lives of the 50+ million Americans living with autoimmune disease.
Philanthropic capital deployed with venture discipline — unlocking early-stage programs that traditional capital passes over.
Two decades of venture investing and nonprofit leadership, aligned around a single goal: accelerating cures for immune-mediated disease.
Immune Boost Capital (IBC)
Dr. Sai Nandi leads Immune Boost Capital, guiding the firm's strategic vision and overseeing its venture investment portfolio. He is a seasoned life sciences investor and operator with more than two decades of leadership at the intersection of venture capital, institutional investing, and company building.
Arthritis National Research Foundation (ANRF)
Emily Boyd Stormoen has more than 20 years of progressive experience working in the nonprofit sector as a senior executive leader, focusing on business development, strategic planning and revenue generation.
A cross-disciplinary board spanning biotech, clinical medicine, capital markets, and operational leadership.
Chair, IBC
Thermo Fisher Scientific
Vice Chair, IBC
Treasurer, IBC
Johnson & Johnson Innovative Medicine
Secretary, IBC
Dalena Capital
Board Member, IBC
Retired, Dell Technologies
Board Member, IBC
JPA Health
Board Member, IBC
Life Sciences
Board Member, IBC
Certara
Whether you're a scientist with a breakthrough, a founder building the next therapy, or a donor who believes in compounding impact — there's a place for you at Immune Boost Capital.
